High throughput genetic analysis of congenital myasthenic syndromes using resequencing microarrays.

backgroundThe use of resequencing microarrays for screening multiple, candidate disease loci is a promising alternative to conventional capillary sequencing. We describe the performance of a custom resequencing microarray for mutational analysis of Congenital Myasthenic Syndromes (CMSs), a group of disorders in which the normal process of neuromuscular transmission is impaired. METHODOLOGY/PRINCIPAL

findingsOur microarray was designed to assay the exons and flanking intronic regions of 8 genes linked to CMSs. A total of 31 microarrays were hybridized with genomic DNA from either individuals with known CMS mutations or from healthy controls. We estimated an overall microarray call rate of 93.61%, and we found the percentage agreement between the microarray and capillary sequencing techniques to be 99.95%. In addition, our microarray exhibited 100% specificity and 99.99% reproducibility. Finally, the microarray detected 22 out of the 23 known missense mutations, but it failed to detect all 7 known insertion and deletion (indels) mutations, indicating an overall sensitivity of 73.33% and a sensitivity with respect to missense mutations of 95.65%. CONCLUSIONS/SIGNIFICANCE: Overall, our microarray prototype exhibited strong performance and proved highly efficient for screening genes associated with CMSs. Until indels can be efficiently assayed with this technology, however, we recommend using resequencing microarrays for screening CMS mutations after common indels have been first assayed by capillary sequencing.